The Federal Medical-Biological Agency (FMBA) has announced the start of clinical use of the new Russian radiopharmaceutical drug "Rakurs, 223Ra." The drug, developed in Dimitrovgrad, has already been delivered to specialized medical institutions and is intended for the treatment of patients with bone metastases in oncological diseases.
The drug contains the radionuclide radium-223, which selectively accumulates in areas of bone tissue affected by metastases. Its alpha radiation locally affects tumor cells, minimizing damage to surrounding healthy tissues.
According to the FMBA, therapy using "Rakurs, 223Ra" helps to reduce pain, slow disease progression, and improve the quality of life of patients.
As noted by the agency, the registration and implementation of the drug is an important step not only in improving the effectiveness of cancer care, but also in ensuring the technological sovereignty of the country in the field of nuclear medicine. The development of a domestic analogue eliminates dependence on imported analogues and expands the availability of advanced treatment methods for Russian patients.